Development of subtype-selective covalent ligands for the adenosine A
Bert L H Beerkens, Xuesong Wang, Maria Avgeropoulou, Lisa N Adistia, Jacobus P D van Veldhoven, Willem Jespers, Rongfang Liu, Laura H Heitman, Adriaan P IJzerman, Daan van der Es
Article in RSC medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 1 institution in 1 country.
Bert L H BeerkensDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.ORCID https://orcid.org/0000-0002-2884-3961
Xuesong WangDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Maria AvgeropoulouDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Lisa N AdistiaDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Jacobus P D van VeldhovenDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Willem JespersDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Rongfang LiuDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Laura H HeitmanDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Adriaan P IJzermanDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.
Daan van der EsDivision of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University Einsteinweg 55 2333 CC Leiden The Netherlands d.van.der.es@lacdr.leidenuniv.nl.ORCID https://orcid.org/0000-0003-3662-8177
Leiden University · NL
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Signalling through the adenosine receptors (ARs), in particular through the adenosine A
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of subtype-selective covalent ligands for the adenosine A · full record | OpenQuestion